Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1991 Sep;66(3):206–211. doi: 10.1136/hrt.66.3.206

Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

R J MacFadyen 1, K R Lees 1, J L Reid 1
PMCID: PMC1024645  PMID: 1657084

Abstract

OBJECTIVE--To compare the first dose responses to low dose angiotensin converting enzyme inhibitors (captopril, enalapril, and perindopril) in elderly patients with stable chronic heart failure. DESIGN--Double blind, randomised, placebo controlled, parallel, group prospective study of elderly patients with stable chronic heart failure. SETTING--General hospital in-patient admissions for supervised diuretic withdrawal (24-48 hours) and the introduction of angiotensin converting enzyme inhibitor therapy. PATIENTS--48 unselected elderly (58-85 years) patients with symptomatic but stable chronic heart failure (New York Heart Association grades II-IV) confirmed by clinical history, examination, and cardiological investigations. Patients gave their written and informed consent to receive their initial treatment under double blind conditions; blood pressure was monitored and blood samples taken to measure the pharmacokinetic and neurohormonal responses. INTERVENTION--Patients were randomised to receive a daily oral dose of placebo, captopril (6.25 mg), enalapril (2.5 mg), or perindopril (2 mg). MAIN OUTCOME MEASURES--Blood pressure and heart rate responses, drug concentration, and plasma renin and ACE activities. Differences between treatment groups were analysed by analysis of variance. RESULTS--The four randomised groups of patients had similar age, severity of heart failure (NYHA class), pretreatment diuretic dosage, plasma renin activity, and serum electrolyte state. Placebo treatment caused a modest but significant diurnal fall in blood pressure. Captopril produced a significant early (1.5 hours) and brief fall in blood pressure. The blood pressure fall with enalapril was later (4-10 hours), longer lasting, and was associated with significant slowing of supine heart rate. Though perindopril produced a similar plasma ACE inhibition to that produced by enalapril, it only caused changes in blood pressure that were similar to those caused by placebo. CONCLUSIONS--This controlled study is the first to indicate a qualitative difference in the acute response to angiotensin converting enzyme inhibitors with similar structure and metabolism (that is, enalapril and perindopril). Low dose perindopril seems to be less likely to cause hypotension in patients with heart failure. The explanation for the differences is unclear but may reflect differential effects on local tissue angiotensin generation.

Full text

PDF
206

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajayi A. A., Lees K. R., Reid J. L. Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. Eur J Clin Pharmacol. 1986;30(2):177–182. doi: 10.1007/BF00614298. [DOI] [PubMed] [Google Scholar]
  2. Anand I. S., Ferrari R., Kalra G. S., Wahi P. L., Poole-Wilson P. A., Harris P. C. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989 Aug;80(2):299–305. doi: 10.1161/01.cir.80.2.299. [DOI] [PubMed] [Google Scholar]
  3. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Belz G. G., Kirch W., Kleinbloesem C. H. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet. 1988 Nov;15(5):295–318. doi: 10.2165/00003088-198815050-00003. [DOI] [PubMed] [Google Scholar]
  5. Boni E., Alicandri C., Fariello R., Zaninelli A., Cantalamessa A., Corda L., Muiesan G. Effect of enalapril on parasympathetic activity. Cardiovasc Drugs Ther. 1990 Feb;4(1):265–268. doi: 10.1007/BF01857643. [DOI] [PubMed] [Google Scholar]
  6. Bounhoure J. P., Bottineau G., Lechat P., Garnham J., Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study. Clin Exp Hypertens A. 1989;11 (Suppl 2):575–586. [PubMed] [Google Scholar]
  7. Campbell B. C., Sturani A., Reid J. L. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci (Lond) 1985 Jan;68(1):49–56. doi: 10.1042/cs0680049. [DOI] [PubMed] [Google Scholar]
  8. Chiknas S. G. A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem. 1979 Jul;25(7):1259–1262. [PubMed] [Google Scholar]
  9. Chimienti M., Moizi M., Klersy C., Guasti L., Salerno J. A. A modified ajmaline test for prediction of the effective refractory period of the accessory pathway in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1987 Jan 1;59(1):164–165. doi: 10.1016/s0002-9149(87)80094-2. [DOI] [PubMed] [Google Scholar]
  10. Cleland J. G., Dargie H. J., McAlpine H., Ball S. G., Morton J. J., Robertson J. I., Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) 1985 Nov 9;291(6505):1309–1312. doi: 10.1136/bmj.291.6505.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Colucci R. D., Auty R., Scavone J., Glassner-Cohen L. The chemical stability of captopril capsules. Int J Clin Pharmacol Ther Toxicol. 1989 Dec;27(12):599–601. [PubMed] [Google Scholar]
  12. Derkx F. H., Tan-Tjiong H. L., Man in 't Veld A. J., Schalekamp M. P., Schalekamp M. A. Activation of inactive plasma renin by plasma and tissue kallikreins. Clin Sci (Lond) 1979 Oct;57(4):351–357. doi: 10.1042/cs0570351. [DOI] [PubMed] [Google Scholar]
  13. Erdös E. G. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension. 1990 Oct;16(4):363–370. doi: 10.1161/01.hyp.16.4.363. [DOI] [PubMed] [Google Scholar]
  14. Fabris B., Jackson B., Kohzuki M., Perich R., Johnston C. I. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol. 1990 Apr;17(4):309–314. doi: 10.1111/j.1440-1681.1990.tb01326.x. [DOI] [PubMed] [Google Scholar]
  15. Flynn K., Coughlan M. G., Phelan D. M., Luke D., Neligan M., Wood A. E. Intravenous captopril in acute heart failure. Lancet. 1988 Jan 23;1(8578):173–174. doi: 10.1016/s0140-6736(88)92737-7. [DOI] [PubMed] [Google Scholar]
  16. Lees K. R., MacFadyen R. J., Reid J. L. Tissue angiotensin converting enzyme inhibition. Relevant to clinical practice? Am J Hypertens. 1990 Nov;3(11):266S–272S. doi: 10.1093/ajh/3.11s.266s. [DOI] [PubMed] [Google Scholar]
  17. Mark A. L. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol. 1983 Jan;1(1):90–102. doi: 10.1016/s0735-1097(83)80014-x. [DOI] [PubMed] [Google Scholar]
  18. Massie B. M., Kramer B. L., Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984 Jun;69(6):1135–1141. doi: 10.1161/01.cir.69.6.1135. [DOI] [PubMed] [Google Scholar]
  19. McMurray J., Lang C. C., Maclean D. D., McDevitt D. G., Struthers A. D. A survey of current use of angiotensin-converting-enzyme inhibitors by Scottish physicians in the treatment of chronic cardiac failure. Scott Med J. 1989 Apr;34(2):425–427. doi: 10.1177/003693308903400204. [DOI] [PubMed] [Google Scholar]
  20. Mujais S. K., Fouad F. M., Textor S. C., Tarazi R. C., Bravo E. L., Hart N., Gifford R. W., Jr Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J. 1984 Jul;52(1):63–71. doi: 10.1136/hrt.52.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Packer M., Gottlieb S. S., Blum M. A. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med. 1987 Mar 20;82(3A):4–10. doi: 10.1016/0002-9343(87)90126-4. [DOI] [PubMed] [Google Scholar]
  22. Packer M., Medina N., Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation. 1985 Apr;71(4):761–766. doi: 10.1161/01.cir.71.4.761. [DOI] [PubMed] [Google Scholar]
  23. Packer M., Medina N., Yushak M., Lee W. H. Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. Br Heart J. 1985 Sep;54(3):298–304. doi: 10.1136/hrt.54.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Porter T. R., Eckberg D. L., Fritsch J. M., Rea R. F., Beightol L. A., Schmedtje J. F., Jr, Mohanty P. K. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest. 1990 May;85(5):1362–1371. doi: 10.1172/JCI114580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reid J. L. Angiotensin converting enzyme inhibitors in the elderly. Br Med J (Clin Res Ed) 1987 Oct 17;295(6604):943–944. doi: 10.1136/bmj.295.6604.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Riegger A. J. ACE inhibitors in congestive heart failure. Cardiology. 1989;76 (Suppl 2):42–49. doi: 10.1159/000174558. [DOI] [PubMed] [Google Scholar]
  27. Semple P. F., Thorén P., Lever A. F. Vasovagal reactions to cardiovascular drugs: the first dose effect. J Hypertens. 1988 Aug;6(8):601–606. doi: 10.1097/00004872-198808000-00001. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES